alpha-aminopyridine has been researched along with Milk-Alkali Syndrome in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abedini, A; Auguste, A; Bertos, N; Cencic, R; Chen, H; Clarke, BA; de Rink, I; Dostie, J; Firlit, M; Foulkes, WD; Gotlieb, WH; Guiot, MC; Hass, R; Huang, S; Jelinic, P; Johnson, RM; Judkins, AR; Kerkhoven, RM; Kong, T; Leary, A; Levine, DA; Macdonald, E; Martinez, D; Meehan, B; Morin, G; Papadakis, AI; Park, M; Patibandla, J; Pelletier, J; Rak, J; Vanderhyden, B; Venneti, S; Wang, XQD; Witcher, M; Witkowski, L; Xue, Y | 1 |
1 other study(ies) available for alpha-aminopyridine and Milk-Alkali Syndrome
Article | Year |
---|---|
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Topics: Aminopyridines; Animals; Benzimidazoles; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Cyclin D1; DNA Helicases; Female; Humans; Hypercalcemia; Mice; Mice, SCID; Nuclear Proteins; Ovarian Neoplasms; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; RNA, Small Interfering; Transcription Factors | 2019 |